Recently, Ligorio [13] reported that PIV showed a better association with survival and outperformed NLR and PLR in predicting survival in patients with human epidermal growth factor receptor 2-positive advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.